Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 9 Carcinoma, Hepatocellular 9 Esophageal Neoplasms 7 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Rectal Neoplasms 4 Nasopharyngeal Carcinoma 4 Colorectal Neoplasms 4 Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Colonic Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Hodgkin Disease 2 Glioblastoma 2 mCRPC 1 Uterine Cervical Neoplasms 1 Unresectable Stage III Non-small Cell Lung Cancer 1 Tongue Squamous Cell Carcinoma 1 SCLC, Extensive Stage 1 Rare Tumour 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Squamous Non-small Cell Lung Cancer 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 NSCLC 1 MSI-H Colorectal Cancer 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × tislelizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡